Day: December 24, 2025

Faraday Future and RAK Digital Assets Oasis (also known as RAK Innovation City) have entered into a strategic non-binding MOU to collaborate across three key areas: AI, Web3 and embodied intelligence. The two parties intend to explore the joint establishment of research and innovation centers to build a forward-looking, demonstrative industrial ecosystem. FF delivered the FX Super One to RAK Innovation City, the second FX Super One delivery in the UAE. The first FX Super One user in the UAE is global football legend Andrés Iniesta. FF has completed the delivery and transaction process for the Company’s next FF 91 2.0 Futurist Alliance vehicle with Hebron Sher, Co-Founder & CEO of ZEVO, with an upcoming delivery ceremony in January 2026.RAS AL KHAIMAH, United Arab Emirates and LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) —...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Canterra Minerals Corporation (TSXV:CTM) (OTCQB:CTMCF) (FSE:DXZB) (“Canterra” or the “Company”) is pleased to announce the closing of its previously announced private placement (see news releases dated December 4, 2025 and December 19, 2025) consisting of Critical Minerals flow-through shares and National flow-through shares for total gross proceeds of $5,705,361.51. (the “Private Placement”). Pursuant to the Private Placement the Company issued 10,980,000 Critical Minerals flow-through shares at a price of $0.25 per share (each, a “CMFT Share”) for gross proceeds of C$2,745,000. Each CMFT Share comprises one common share of the Company (each, a “Common Share”) issued as a flow-through...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication  AQVESME expected to be available in late January 2026, following AQVESME REMS program implementation Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ETCAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQVESME™ (mitapivat), an oral pyruvate kinase (PK)...